A Pilot Study To Assess the Suitability of Riboflavin As a Surrogate Marker of Breast Cancer Resistance Protein in Healthy Participants

• Published in: The Journal of pharmacology and experimental therapeutics Vol. 390; no. 2; pp. 162 - 173
• Main Authors: Shen, Hong, Huo, Runlan, Zhang, Yueping, Wang, Linna, Tong, Nian, Chen, Weiqi, Paris, Andrew J., Mensah, Kofi, Chen, Min, Xue, Yongjun, Li, Wenying, Sinz, Michael
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Inc 01.08.2024
• Subjects: Adult; ATP Binding Cassette Transporter, Subfamily G, Member 2 - antagonists & inhibitors; ATP Binding Cassette Transporter, Subfamily G, Member 2 - metabolism; Biomarkers - blood; Biomarkers - metabolism; Healthy Volunteers; Humans; Male; Methotrexate - blood; Methotrexate - metabolism; Methotrexate - pharmacokinetics; Methotrexate - pharmacology; Middle Aged; Neoplasm Proteins - antagonists & inhibitors; Neoplasm Proteins - metabolism; Pilot Projects; Riboflavin - blood; Riboflavin - metabolism; Riboflavin - pharmacokinetics; Young Adult; OCT; FDA; LLC-PK1; OAT; E3S; Cmax,u; DDI; Cmax,inlet,u; AUC; MTX; eV; LC-MS/MS; QC; EMA; CCK-8; m/z; MDR; AUC(0–24h); HPLC; BCRP; E17βG; P-gp; CI; MATE; PYR; IR; OATP; ER; GMR; RIF; HEK; PROB; PAH; Tmax; AUC(0–4h); NER; HBSS; SSZ; AUCR; Igut

We recently showed that riboflavin is a selected substrate of breast cancer resistance protein (BCRP) over P-glycoprotein (P-gp) and demonstrated its prediction performance in preclinical drug-drug interaction (DDI) studies. The aim of this study was to investigate the suitability of riboflavin to a...